What are the treatment options for genital warts?

Treatment of Genital Warts

For genital warts, treatment should be divided into patient-applied therapies (podofilox 0.5% solution preferred) and provider-administered therapies (cryotherapy, surgical excision, or TCA/BCA), with selection based on wart characteristics, patient preference, and treatment availability. 1

Key Clinical Context

• Spontaneous regression is common: 60-80% of genital warts regress within the first year without treatment, though this should not delay therapy in symptomatic patients 2
• Most warts respond within 3 months of therapy, and treatment should be reassessed if no response occurs by this timeframe 1
• All treatments have recurrence rates, but most successfully treated warts do not recur 3

Patient-Applied Therapies (First-Line Options)

Podofilox 0.5% Solution or Gel

• Most effective patient-administered therapy 3
• Apply twice daily for 3 consecutive days, followed by 4 days off-therapy 1
• Repeat cycle up to 4 times as needed 1
• Limit treatment to <10 cm² total area and <0.5 mL volume per day 1
• Provider should demonstrate initial application technique 1
• Contraindicated in pregnancy 3

Imiquimod 5% Cream

• Apply once daily at bedtime, 3 times per week for up to 16 weeks 1
• Wash off with soap and water 6-10 hours after application 1
• Stimulates interferon and cytokine production 1
• Common side effects: local inflammatory reactions (erythema, irritation, ulceration), hypopigmentation 1
• May weaken condoms and diaphragms 1
• Contraindicated in pregnancy 3

Imiquimod 3.75% Cream (FDA-Approved Alternative)

• Apply once daily (instead of 3 times weekly) for up to 8 weeks 2
• Clearance rate 27-29% vs 9-10% with placebo at 16 weeks 2
• Approved for patients ≥12 years with external genital warts 2
• Not evaluated in pregnancy, immunosuppressed patients, or intravaginal/anal warts 2

Sinecatechins 15% Ointment

• Green tea extract applied 3 times daily until complete clearance, maximum 16 weeks 1
• Apply 0.5-cm strand to each wart; do not wash off 1
• Avoid sexual contact while ointment is on skin 1
• Not recommended for HIV-infected or immunocompromised patients 1
• Contraindicated in pregnancy 3
• May weaken condoms and diaphragms 1

Provider-Administered Therapies (First-Line Options)

Cryotherapy with Liquid Nitrogen

• First-line destructive treatment based on cost-effectiveness 4
• Repeat applications every 1-2 weeks until clearance 1
• Destroys warts through thermal-induced cytolysis 1
• Requires proper training to avoid over- or under-treatment complications 1

Trichloroacetic Acid (TCA) or Bichloroacetic Acid (BCA) 80-90%

• Apply directly to warts; allow to dry until white "frosting" develops 1
• Repeat weekly as needed 1
• Can be used in pregnancy 1
• Inconsistent efficacy limits use as primary treatment 4

Surgical Removal

• Most effective for wart removal at end of treatment (along with CO₂ laser and electrosurgery) 3
• Options include tangential scissor excision, tangential shave excision, curettage, or electrosurgery 1
• Preferred for large wart burden or when rapid clearance needed 1

Carbon Dioxide Laser Therapy

• Most effective for wart removal 3
• Requires specialized equipment and training 4
• Higher cost limits routine use 4

Alternative/Second-Line Therapies

Podophyllin Resin 10-25%

• Should be considered alternative therapy only due to severe toxicity reports with misuse 2
• Apply to each wart, allow to dry, repeat weekly if needed 2
• Limit to <0.5 mL per application to avoid systemic absorption 2
• Case reports of death and fetal loss with misapplication 2
• Given availability of safer alternatives, use only with strict adherence to guidelines 2

Other Options

• 5-fluorouracil, local interferon, and photodynamic therapy evaluated as potential second-line treatments 5
• Interferon too expensive for primary treatment 4

Treatment Selection Algorithm

Choose based on:

1. Wart characteristics: Number, size, location, keratinization 1
2. Patient factors: Pregnancy status, immunosuppression, ability to apply medication correctly 1
3. Resource availability: Provider skills, clinic equipment, medication cost 3
4. Patient preference: Home vs office-based treatment 1

For small, non-keratinized external warts: Start with patient-applied podofilox 0.5% 3

For larger wart burden or need for rapid clearance: Provider-administered cryotherapy or surgical excision 1, 3

For pregnancy: TCA/BCA only safe option; avoid all patient-applied therapies 1, 3

For immunocompromised/HIV patients: Avoid sinecatechins; consider surgical options 1

Important Caveats

• Persistent pigmentation changes (hypo- or hyperpigmentation) common with ablative and immune-modulating therapies 1
• Scarring (depressed or hypertrophic) can occur if insufficient healing time between treatments 1
• Chronic pain syndromes (vulvodynia, hyperesthesia, painful defecation, fistulas) are rare but serious complications 1
• Healthcare worker protection: Use PPE (goggles, masks) and smoke evacuators during electrosurgical procedures due to HPV DNA in plume 2
• No single therapy has emerged as definitive standard of care; treatment remains patient-specific 6